Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan Grants Orphan Status to Vanda, Quoin Drugs, and Lots More
Japan’s Ministry of Health, Labor and Welfare (MHLW) on June 23 doled out orphan drug designations to a raft of compounds including Vanda Pharmaceuticals’ imsidolimab for pustular psoriasis and Quoin Pharmaceuticals’ dipalmitoyl hydroxyproline for Netherton syndrome. Takeda Pharmaceutical’s vedolizumab was…
To read the full story
Related Article
- Novo’s Wegovy Nears Japan Approval as First MASH Therapy
June 1, 2026
- AstraZeneca’s Oral SERD, MSD RSV Antibody Clear Japan Panel Review
May 26, 2026
- Jazz, Nippon Zoki Ink Deal to Bring Cannabis-Derived Epilepsy Drug to Japan
April 22, 2026
- Stella Pharma Files Steboronine for Recurrent Meningioma
March 18, 2026
- Japan Grants Orphan Tag to Cannabidiol, 6 More APIs
June 10, 2024
REGULATORY
- CEA Review Has not Settled Debate, LDP Lawmaker Says
September 15, 2026
- Japan Pharma Investment Subgroup to Hold 1st Meeting September 18
September 14, 2026
- Japan Formally Joins Project Orbis for Cancer Drug Reviews
September 14, 2026
- MHLW Seeks 20.6 Billion Yen for MCM Stockpiles, Revenue Guarantees
September 14, 2026
- Japan Panel Backs Mandatory Medical Data Sharing by Major Hospitals
September 14, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…